The Effect of Pregnancy and Inflammatory Bowel Disease on the Pharmacokinetics of Drugs Related to Inflammatory Bowel Disease—A Systematic Literature Review
Due to ethical and practical reasons, a knowledge gap exists on the pharmacokinetics (PK) of inflammatory bowel disease (IBD)-related drugs in pregnant women with IBD. Before evidence-based dosing can be proposed, insight into the PK has to be gained to optimize drug therapy for both mother and fetu...
Main Authors: | Thomas K. Wiersma, Marijn C. Visschedijk, Nanne K. de Boer, Marjolijn N. Lub-de Hooge, Jelmer R. Prins, Daan J. Touw, Paola Mian |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-06-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/6/1241 |
Similar Items
-
Pharmacokinetic Boosting of Kinase Inhibitors
by: Niels Westra, et al.
Published: (2023-04-01) -
Evaluation of the Predictive Performance of Population Pharmacokinetic Models of Adalimumab in Patients with Inflammatory Bowel Disease
by: Silvia Marquez-Megias, et al.
Published: (2021-08-01) -
Prediction of Inflammatory Bowel Disease Course Based on Fecal Scent
by: Sofie Bosch, et al.
Published: (2022-03-01) -
External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease
by: Christina Schräpel, et al.
Published: (2021-08-01) -
Bowel Ultrasound in Inflammatory Bowel Disease: How Far in the Grayscale?
by: Federica Furfaro, et al.
Published: (2021-07-01)